Cipla’s wholly owned United States subsidiary, InvaGen Pharmaceuticals, has entered an exclusive partnership with China’s Qilu Pharmaceutical to license and supply QL2107, a proposed biosimilar to pembrolizumab, in the US market.
How responsibilities are divided
The agreement announced on September 3, 2026 assigns development, regulatory registration and supply responsibilities to Qilu, while Cipla is expected to commercialise the product through InvaGen in the United States.
QL2107 is being developed as a biosimilar to Merck’s Keytruda, whose active ingredient is pembrolizumab. Pembrolizumab is an immunotherapy used for multiple cancers, but the exact approved uses of any biosimilar will depend on regulatory review and its final label.
What a biosimilar is
A biosimilar is a biological medicine shown to be highly similar to an already approved reference product, without clinically meaningful differences in safety, purity and potency. It is not a conventional chemical generic because biological products are larger and more complex.
The partnership announcement does not mean QL2107 has already received approval from the US Food and Drug Administration. Development evidence and a regulatory application must support any future commercial launch.
Potential effect on access
Cipla said the partnership aims to improve access to advanced cancer treatment. Biosimilar competition can reduce treatment costs, but the actual price and patient savings will depend on approval, contracting, insurance coverage and market competition.
No launch date or US price was disclosed in the reviewed announcement. It would therefore be inaccurate to claim immediate availability or a fixed reduction in treatment cost.
Strategic importance for Cipla
The agreement gives Cipla a route into a major biologics market through a product developed by Qilu. For Qilu, Cipla and InvaGen provide a commercial platform in the United States.
Reuters independently confirmed the core terms and described the partnership as part of Cipla’s push to strengthen its position in US biologics. Financial terms were not made public.
What happens next
Important milestones include completion of development work, submission of regulatory data, FDA review and any decision on interchangeability or approved indications. Manufacturing quality and pharmacovigilance will remain central if the product reaches patients.
Until approval is granted, QL2107 should be described as a proposed biosimilar rather than an approved alternative to Keytruda.
